TrialAnnals of the rheumatic diseases2013

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).

Maxime Dougados et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.